This profile was last updated on .
Is this you? Claim your profile.
+ Get 10 Free Contacts a Month
Please agree to the terms and conditions
105 Digital Drive
Novato, California 94949
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. Approved products i ... more
Vice President of Research and Development
Scientific Advisory Board Member
Member, Scientific Advisory Board
Oklahoma Center for Molecular Medicine
University of Cincinnati Medical School
BioMarin : About Us : Leadership Team : Management Team
A report issued by the Alzheimer's Association in March 2007 puts the number of people with AD who are younger than 65 at around 200,000 in the U.S.
"Ironically, most all the research on Alzheimer's is being done with mice that have been bred to develop the Familial type, even though the target is the much larger Alzheimer's population," said Dr. Vehar.
"Drug development is a very high-risk area," Vehar said.
has an above-average record for moving its drugs into clinical trials, with 25 to 30 percent of its animal-tested drugs receiving approvals for humans, Vehar said.
But industry-wide, fewer than 10 percent of drugs targeting the central nervous system - Alzheimer's falls into that category - advance from clinical trials to the marketplace, Vehar said.
The new research will focus specifically on a rare type of inherited, early onset Alzheimer's that affects patients as young as 30.
The early onset form of the disease affects only about 34,000 patients.
Focusing on a rare disorder follows BioMarin's typical approach to drug research, Vehar said.
The company looks for disorders that affect relatively small populations and are linked to specific genes,
Gordon Vehar, Ph.D. - BioMarin Executive Team - Management
Texas Music Educators Association
University of California , San Diego
Sandia National Laboratories